The Joint (JYNT)
(Delayed Data from NSDQ)
$10.43 USD
-0.20 (-1.88%)
Updated Jan 2, 2025 04:00 PM ET
After-Market: $10.44 +0.01 (0.10%) 7:34 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.43 USD
-0.20 (-1.88%)
Updated Jan 2, 2025 04:00 PM ET
After-Market: $10.44 +0.01 (0.10%) 7:34 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Zacks News
JYNT's Q3 Earnings Meet Estimates Amid Higher Costs, Shares Dip 3%
by Zacks Equity Research
The Joint's Q3 results reflect higher general and administrative costs. Revenues benefit from strong royalty fees and advertising revenues.
The Joint Corp. (JYNT) Q3 Earnings Match Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of 0% and 5.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.02% and 6.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 16.55% and 10.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth Group (UNH) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 1.85% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) Forays Into San Francisco Chiropractic Market
by Zacks Equity Research
This year, The Joint (JYNT) intends to open 60-70 new franchised clinics compared with 104 opened last year.
The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of -500% and 2.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.67% and 3.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine
by Zacks Equity Research
Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.
Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues
by Zacks Equity Research
Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.
Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio
by Zacks Equity Research
Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.
Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY
by Zacks Equity Research
Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.
Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout
by Zacks Equity Research
By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.
Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab
by Zacks Equity Research
Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
by Zacks Equity Research
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
National Vision (EYE) Gains Market Share Despite Macro Woes
by Zacks Equity Research
National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.
Thermo Fisher (TMO) Expands Central Lab Footprint in Kentucky
by Zacks Equity Research
Thermo Fisher (TMO) announces expansion of its central laboratory operations in Kentucky. The new space in Covington will be in addition to its existing central lab in Highland Heights.
Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch
by Zacks Equity Research
Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.
Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.
Charles River (CRL) Inks CDMO Deal With Gates Institutes
by Zacks Equity Research
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance
by Zacks Equity Research
Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS
by Zacks Equity Research
Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.
Inspira (IINN) Unveils Business Targets for 2024-25
by Zacks Equity Research
Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).
Thermo Fisher (TMO) Unveils New Research Laboratory in WI
by Zacks Equity Research
Thermo Fisher (TMO) announces a new 72,500-square-foot clinical research laboratory building at its good manufacturing practices lab in Middleton, WI
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.